Covishield Row: Plea In Supreme Court Seeks Probe Into Vaccine Side Effects
A plea has been filed in the Supreme Court for a formation of an expert panel to examine the side effects and risk factors associated with AstraZeneca's Covishield vaccine. The plea, filed by advocate Vishal Tiwari, seeks to nudge the top court to issue directions to the Union government regarding the establishment of a vaccine damage payment system for those citizens who got severely affected as a result of the vaccination drive during Covid-19.
AstraZeneca's vaccine formula was licensed to Serum Institute of India and manufactured in the country as Covishield. According to the plea, more than 175 crore doses of Covishield have been administered in India.
AstraZeneca has said that its vaccine against Covid-19 could cause low platelet counts and formation of blood clots in "very rare" cases. The plea pointed out that AstraZeneca accepted a link between the vaccine and thrombosis with thrombocytopenia syndrome, a medical condition characterised by abnormally low platelet level and the formation of blood clots.
Thrombosis With Thrombocytopenia Syndrome
The symptoms of TTS include breathlessness, pain in the chest or limbs, pinhead-size red spots or bruising of the skin in an area beyond the injection site, headaches, numbness in body parts, blurred vision, seizures and drowsiness.
Since a large number of Covishield vaccines were administered to Indian citizens on the assurance of the government regarding its safety, the plea seeks responsibility on the government's part so that it takes immediate steps for the health and safety of its citizens. It said the Union government must prioritise addressing this issue to prevent future risks to the health and lives of Indian citizens.
-
We May Need Another Tukaram Mundhe To Fight Air Pollution | The Reason Why
Developers may install basic measures such as sprinklers and green nets, resume work, and continue violating rules when this equipment stops working.
-
Extracting Value From Battery Scrap Could Be Challenging For India | The Reason Why
A discarded lithium-ion battery still contains valuable materials such as lithium, nickel and cobalt. These can be recovered and reused. When such batteries are crushed and shredded, they produce a dark powder called black mass.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.